-
Frank Gehry, master architect with a flair for drama, dead at 96
-
'It doesn't make sense': Trump wants to rename American football
-
A day after peace accord signed, shelling forces DRC locals to flee
-
Draw for 2026 World Cup kind to favorites as Trump takes center stage
-
Netflix to buy Warner Bros. in deal of the decade
-
US sanctions equate us with drug traffickers: ICC dep. prosecutor
-
Migration and crime fears loom over Chile's presidential runoff
-
French officer charged after police fracture woman's skull
-
Fresh data show US consumers still strained by inflation
-
Eurovision reels from boycotts over Israel
-
Trump takes centre stage as 2026 World Cup draw takes place
-
Trump all smiles as he wins FIFA's new peace prize
-
US panel votes to end recommending all newborns receive hepatitis B vaccine
-
Title favourite Norris reflects on 'positive' Abu Dhabi practice
-
Stocks consolidate as US inflation worries undermine Fed rate hopes
-
Volcanic eruptions may have brought Black Death to Europe
-
Arsenal the ultimate test for in-form Villa, says Emery
-
Emotions high, hope alive after Nigerian school abduction
-
Another original Hermes Birkin bag sells for $2.86 mn
-
11 million flock to Notre-Dame in year since rising from devastating fire
-
Gymnast Nemour lifts lid on 'humiliation, tears' on way to Olympic gold
-
Lebanon president says country does not want war with Israel
-
France takes anti-drone measures after flight over nuclear sub base
-
Signing up to DR Congo peace is one thing, delivery another
-
'Amazing' figurines find in Egyptian tomb solves mystery
-
Palestinians say Israeli army killed man in occupied West Bank
-
McLaren will make 'practical' call on team orders in Abu Dhabi, says boss Brown
-
Norris completes Abu Dhabi practice 'double top' to boost title bid
-
Chiba leads Liu at skating's Grand Prix Final
-
Meta partners with news outlets to expand AI content
-
Mainoo 'being ruined' at Man Utd: Scholes
-
Guardiola says broadcasters owe him wine after nine-goal thriller
-
Netflix to buy Warner Bros. Discovery in deal of the decade
-
French stars Moefana and Atonio return for Champions Cup
-
Penguins queue in Paris zoo for their bird flu jabs
-
Netflix to buy Warner Bros. Discovery for nearly $83 billion
-
Sri Lanka issues fresh landslide warnings as toll nears 500
-
Root says England still 'well and truly' in second Ashes Test
-
Chelsea's Maresca says rotation unavoidable
-
Italian president urges Olympic truce at Milan-Cortina torch ceremony
-
Norris edges Verstappen in opening practice for season-ending Abu Dhabi GP
-
Australia race clear of England to seize control of second Ashes Test
-
Trump strategy shifts from global role and vows 'resistance' in Europe
-
Turkey orders arrest of 29 footballers in betting scandal
-
EU hits X with 120-mn-euro fine, risking Trump ire
-
Arsenal's Merino has earned striking role: Arteta
-
Putin offers India 'uninterrupted' oil in summit talks with Modi
-
New Trump strategy vows shift from global role to regional
-
World Athletics ditches long jump take-off zone reform
-
French town offers 1,000-euro birth bonuses to save local clinic
| RIO | -1.01% | 72.99 | $ | |
| CMSC | -0.1% | 23.456 | $ | |
| BTI | -1.62% | 57.115 | $ | |
| NGG | -0.54% | 75.5 | $ | |
| GSK | -0.69% | 48.235 | $ | |
| RYCEF | -0.96% | 14.51 | $ | |
| AZN | 0.13% | 90.15 | $ | |
| BP | -3.42% | 36 | $ | |
| RBGPF | 0% | 78.35 | $ | |
| VOD | -1.27% | 12.475 | $ | |
| SCS | -0.53% | 16.145 | $ | |
| JRI | 0.12% | 13.767 | $ | |
| BCC | -1.05% | 73.49 | $ | |
| RELX | -0.48% | 40.345 | $ | |
| BCE | 1.59% | 23.594 | $ | |
| CMSD | -0.33% | 23.244 | $ |
Ozempic slimming craze sweeps Kosovo despite side effects
Kosovo influencer Tringa Kadriu sees the slimming drug Ozempic as a chance to shed excess pounds -- and she is not the only one in her Balkan nation, where more than half the population is overweight.
"I want to lose 15-16 kilos (33-35 pounds) in two months," Kadriu, 29, told AFP, "and then I'll continue with fitness".
Ozempic, approved in the United States to treat diabetes in 2017, has found an international market for people trying to lose weight.
Despite its cost, the drug has soared in popularity in Kosovo, a country of 1.7 million.
While Kosovo authorities have not sanctioned the drug's use for weight loss, they have noted their limited means to confront use of a drug widely available in the country.
Merita Emini-Sadiku, who heads the Kosovo university hospital's endocrinology clinic, said the cost of the drug had soared.
"The monthly dose used to be 75-80 euros ($85-91), while now it is 130-140 euros ($147-159), probably due to high demand," she said.
But she warned that "Ozempic has side effects that people are not aware of".
Ozempic use can potentially cause issues including thyroid cancer, pancreatitis, gastroparesis and bowel obstruction, according to the latest studies.
- 'Constant demand' -
Meant to treat Type 2 diabetes -- of which the WHO says Kosovo has lower than average levels -- the drug regulates blood sugar levels but also helps suppress hunger, leading to a lower calorie intake.
As a result, its potentially cancerous complications have done little to stem the drug's popularity or availability.
"I checked a lot of pharmacies in Kosovo and I noticed that Ozempic is very easy to get," said Kadriu, adding that pharmacists even suggested she gradually increase her dosage.
A worker at a pharmacy in the capital Pristina's downtown, who asked to remain anonymous, said she had trouble recalling when someone last came into her pharmacy to buy Ozempic with a diabetes prescription.
"But we have a constant demand for Ozempic without a prescription. You can guess why," she said.
Given its availability, Emini-Sadiku said authorities should exercise greater control over Ozempic's distribution.
But Bujar Vitija, a journalist specialising in health, said that would be tricky to achieve given Kosovo's poor health record-keeping.
"Unfortunately there is no data," Vitija said.
With 1,500 to 1,600 private pharmacies in Kosovo, the country's 20 pharmaceutical inspectors have their work cut out for them, he added.
- Ozempic 'every day' -
While Kosovo has lower levels of obesity than the European average, more than 57 percent of the population is overweight and 20 percent is clinically obese, according to a 2019 World Health Organization report.
And women, who are more likely to face societal pressure to be thin, were 66 percent more likely to be obese than men, the WHO report found.
But not every Kosovar who has used Ozempic had the best experience with the drug.
"I took Ozempic on the advice of a doctor for two years but it had no effect," said 48-year-old merchant Lulzim Rrahmani, adding that three of his relatives even experienced "a negative effect of the drug".
"It was just a waste of money and time."
Given the risk of side effects, Emini-Sadiku said Ozempic was "by no means to be taken without a doctor's prescription".
Yet Kadriu said she would not be deterred, adding that she saw colleagues taking the drug "every day at work".
"I don't see any symptom that would deter me."
P.Serra--PC